Focus: Angitia Biopharmaceuticals is a late-stage bispecific antibody company focused on musculoskeletal and neurology indications, currently advancing a pipeline targeting degenerative disc disease, osteogenesis imperfecta, and osteoporosis. The company raised $130M in Series D funding (Feb 2026) and operates from Woodland Hills, CA.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Angitia is a high-risk, high-reward opportunity for early-stage biotech professionals seeking technical platform depth and Phase 3 visibility, but hiring freeze and pre-revenue status limit career flexibility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Angitia Biopharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Angitia Biopharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data - Endpoints News
Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data Endpoints News
Bain-backed Angitia drops lead spinal fusion candidate - Fierce Biotech
Bain-backed Angitia drops lead spinal fusion candidate Fierce Biotech
Browsing the China marketplace: RA Capital’s high-stakes climb up ‘Mount Biopharma’ - The Pharma Letter
Browsing the China marketplace: RA Capital’s high-stakes climb up ‘Mount Biopharma’ The Pharma Letter
Biopharma bites: Angitia, LB Pharma raise funds, plus Eisai-Henlius deal and CVS formulary updates - FirstWord Pharma
Biopharma bites: Angitia, LB Pharma raise funds, plus Eisai-Henlius deal and CVS formulary updates FirstWord Pharma
Angitia raises $130M to challenge Amgen with bone-building bispecifics - Fierce Biotech
Angitia raises $130M to challenge Amgen with bone-building bispecifics Fierce Biotech
Angitia gets $130M Series D for pipeline of musculoskeletal drugs - Endpoints News
Angitia gets $130M Series D for pipeline of musculoskeletal drugs Endpoints News
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Bispecific antibody against sclerostin and DKK1 improves bone health and reduces bone marrow adipose tissue accumulation in experimental chronic kidney disease.
Bezeotermin Alfa (rhBMP-6) Administration in Lumbar Interbody Fusion Surgery Using a Posterior Approach: A Randomized, Double-Blinded, Placebo-Controlled Phase-2 Study.
Showing 5 of 8 publications